Lucerno's next step for commercial device after $6M funder

Lucerno Dynamics – which recently completed its series A equity funding round, raising $6.34 million – has a commercially available device and has launched a new study with it. The Morrisville-based company’s Class 1 device, the Lara System, is now listed with the U.S. Food and Drug Administration. The device detects and monitors infiltrations of radiotracer injections during PET/CT scans. Consequently, Lucerno has also launched it’s Lara QI study, according to CEO Ron Lattanze. It's aimed…
Source: bizjournals.com Health Care:Biotechnology headlines - Category: Biotechnology Authors: Source Type: news